GENinCode (LON:GENI) Trading Up 8.7% – Still a Buy?

GENinCode Plc (LON:GENI) shares were up 8.7% during mid-day trading on Tuesday . The stock traded as high as GBX 0.98 and last traded at GBX 0.98. Approximately 3,765,810 shares were traded during trading, a decline of 41% from the average daily volume of 6,361,748 shares. The stock had previously closed at GBX 0.90.

GENinCode Stock Down 12.5%

The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74. The firm has a market capitalization of £6.34 million, a P/E ratio of -0.37 and a beta of 0.59. The company has a 50 day simple moving average of GBX 1.09 and a two-hundred day simple moving average of GBX 1.42.

GENinCode (LON:GENI) last announced its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The company had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. On average, equities analysts predict that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.